Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) declining 0.2% and the iShares Biotechnology ETF (IBB) inactive.
Novo Nordisk (NVO) said it has halted its collaboration with Hims & Hers Health (HIMS) on the sale of weight loss drugs, including Wegovy. Hims & Hers Health shares were down more than 23% pre-bell.
Exelixis (EXEL) shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a "statistically significant" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.
Cidara Therapeutics (CDTX) shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.